EmVenio Research and TrialHub Announce Partnership
EmVenio Research has announced a partnership with TrialHub. Through TrialHub's data intelligence gathering platform, EmVenio can identify optimal markets to attract clinical trial participants who are needed to support pharmaceutical sponsors and clinical research organizations' participation goals.
TrialHub's benchmarking and data provide a feasibility overview of the clinical research landscape, allowing EmVenio to strategically select clinical trial site locations based on disease prevalence, recruitment rates, and access to readily available healthcare facilities and practitioners, including underserved communities.
By working with TrialHub, EmVenio will donate a full patient scholarship to the European Patients' Academy on Therapeutic Innovation's Patient Expert program. EUPATI's program focuses on education, inclusivity and stakeholder partnership to enhance patient engagement through accessible and innovative education.
Reference
EmVenio Research and TrialHub partner to optimize patient participation and accelerate site selection for clinical trials. (2023, July 27). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
